Page last updated: 2024-10-19

thioctic acid and Multiple Sclerosis, Chronic Progressive

thioctic acid has been researched along with Multiple Sclerosis, Chronic Progressive in 4 studies

Thioctic Acid: An octanoic acid bridged with two sulfurs so that it is sometimes also called a pentanoic acid in some naming schemes. It is biosynthesized by cleavage of LINOLEIC ACID and is a coenzyme of oxoglutarate dehydrogenase (KETOGLUTARATE DEHYDROGENASE COMPLEX). It is used in DIETARY SUPPLEMENTS.

Multiple Sclerosis, Chronic Progressive: A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing remitting form. If the clinical course is free of distinct remissions, it is referred to as primary progressive multiple sclerosis. When the progressive decline is punctuated by acute exacerbations, it is referred to as progressive relapsing multiple sclerosis. The term secondary progressive multiple sclerosis is used when relapsing remitting multiple sclerosis evolves into the chronic progressive form. (From Ann Neurol 1994;36 Suppl:S73-S79; Adams et al., Principles of Neurology, 6th ed, pp903-914)

Research Excerpts

Excerpt	Relevance	Reference
"Gait and balance impairment is common in secondary progressive multiple sclerosis (SPMS)."	2.87	Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. ( Bourdette, DN; Fling, BW; Horak, FB; Loy, BD; Spain, RI, 2018)

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Cameron, M	1
Taylor, C	1
Lapidus, J	1
Ramsey, K	1
Koop, D	1
Spain, R	2
Fiedler, SE	1
Yadav, V	2
Kerns, AR	1
Tsang, C	1
Markwardt, S	1
Kim, E	1
Bourdette, D	2
Salinthone, S	1
Loy, BD	1
Fling, BW	1
Horak, FB	1
Bourdette, DN	1
Spain, RI	1
Shinto, L	1

Clinical Trials (1)

Trial Overview

Trial			Phase	Enrollment	Study Type	Start Date	Status
Defining the Anti-inflammatory Role of Lipoic Acid in Multiple Sclerosis[NCT00997438]			Phase 1	69 participants (Actual)	Interventional	2010-08-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

cAMP Levels

(NCT00997438)
Timeframe: 2 hours

Intervention	pmol cAMP/mg protein (Median)
MS - Secondary Progressive	75.9
MS - Relapsing Remmitting	75.8
Healthy Controls	96.6

cAMP Levels

(NCT00997438)
Timeframe: 4 hours

Intervention	pmol cAMP/mg protein (Median)
MS - Secondary Progressive	72.6
MS - Relapsing Remmitting	79.1
Healthy Controls	103.5

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 1 hour

Intervention	ng/mL (Mean)
MS - Secondary Progressive	1376.14
MS - Relapsing Remmitting	1609.07
Healthy Controls	1428.05

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 2 hours

Intervention	ng/mL (Mean)
MS - Secondary Progressive	1125.71
MS - Relapsing Remmitting	1167.33
Healthy Controls	1348

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 24 hour

Intervention	ng/mL (Mean)
MS - Secondary Progressive	0.78
MS - Relapsing Remmitting	0.87
Healthy Controls	0.78

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 3 hours

Intervention	ng/mL (Mean)
MS - Secondary Progressive	667.86
MS - Relapsing Remmitting	638.4
Healthy Controls	793.89

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 4 hours

Intervention	ng/mL (Mean)
MS - Secondary Progressive	268.6
MS - Relapsing Remmitting	252.75
Healthy Controls	394.1

Lipoic Acid Levels

Plasma concentration of LA (NCT00997438)
Timeframe: 48 hour

Intervention	ng/mL (Mean)
MS - Secondary Progressive	0.55
MS - Relapsing Remmitting	0.7
Healthy Controls	0.57

RANTES Levels

(NCT00997438)
Timeframe: 24 hour

Intervention	pg/mL (Mean)
MS - Secondary Progressive	47184.9
MS - Relapsing Remitting	36281.4
Healthy Controls	76751.7

RANTES Levels

(NCT00997438)
Timeframe: 48 hour

Intervention	pg/mL (Mean)
MS - Secondary Progressive	44905.8
MS - Relapsing Remmitting	42593.8
Healthy Controls	60578.5

Trials

3 trials available for thioctic acid and Multiple Sclerosis, Chronic Progressive

Article	Year
Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial. Journal of clinical pharmacology, 2020, Volume: 60, Issue:8 Topics: Administration, Oral; Aged; Area Under Curve; Biological Availability; Cross-Over Studies; Double-Bl	2020
Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial. Journal of clinical pharmacology, 2020, Volume: 60, Issue:8 Topics: Administration, Oral; Aged; Area Under Curve; Biological Availability; Cross-Over Studies; Double-Bl	2020
Gastrointestinal Tolerability and Absorption of R- Versus R,S-Lipoic Acid in Progressive Multiple Sclerosis: A Randomized Crossover Trial. Journal of clinical pharmacology, 2020, Volume: 60, Issue:8 Topics: Administration, Oral; Aged; Area Under Curve; Biological Availability; Cross-Over Studies; Double-Bl	2020
Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects. Molecular neurobiology, 2018, Volume: 55, Issue:7 Topics: Administration, Oral; Adult; Aged; Cyclic AMP; Dinoprostone; Dose-Response Relationship, Drug; Femal	2018
Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects. Molecular neurobiology, 2018, Volume: 55, Issue:7 Topics: Administration, Oral; Adult; Aged; Cyclic AMP; Dinoprostone; Dose-Response Relationship, Drug; Femal	2018
Lipoic Acid Stimulates cAMP Production in Healthy Control and Secondary Progressive MS Subjects. Molecular neurobiology, 2018, Volume: 55, Issue:7 Topics: Administration, Oral; Adult; Aged; Cyclic AMP; Dinoprostone; Dose-Response Relationship, Drug; Femal	2018
Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. Complementary therapies in medicine, 2018, Volume: 41 Topics: Exercise Test; Female; Gait; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Pos	2018
Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. Complementary therapies in medicine, 2018, Volume: 41 Topics: Exercise Test; Female; Gait; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Pos	2018
Effects of lipoic acid on walking performance, gait, and balance in secondary progressive multiple sclerosis. Complementary therapies in medicine, 2018, Volume: 41 Topics: Exercise Test; Female; Gait; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Pos	2018

Other Studies

1 other study available for thioctic acid and Multiple Sclerosis, Chronic Progressive

Article	Year
Complementary and alternative medicine for the treatment of multiple sclerosis. Expert review of clinical immunology, 2010, Volume: 6, Issue:3 Topics: Adult; Antioxidants; Clinical Trials as Topic; Complementary Therapies; Diet, Fat-Restricted; Dietar	2010
Complementary and alternative medicine for the treatment of multiple sclerosis. Expert review of clinical immunology, 2010, Volume: 6, Issue:3 Topics: Adult; Antioxidants; Clinical Trials as Topic; Complementary Therapies; Diet, Fat-Restricted; Dietar	2010
Complementary and alternative medicine for the treatment of multiple sclerosis. Expert review of clinical immunology, 2010, Volume: 6, Issue:3 Topics: Adult; Antioxidants; Clinical Trials as Topic; Complementary Therapies; Diet, Fat-Restricted; Dietar	2010